SCHEDULE: Vanguard Group Amends Beam Therapeutics Ownership Filing

The Vanguard Group has filed an amendment to its Schedule 13G for Beam Therapeutics Inc., reporting 0% beneficial ownership due to an internal corporate realignment.

Summary

• The Vanguard Group filed an Amendment No. 3 to its Schedule 13G for Beam Therapeutics Inc. Common Stock.
• The filing indicates that The Vanguard Group now beneficially owns 0.00 shares, representing 0% of the class.
• This change is attributed to an internal realignment within The Vanguard Group, Inc. that occurred on January 12, 2026.
• Following the realignment, certain subsidiaries or business divisions of The Vanguard Group, Inc. will report beneficial ownership separately (on a disaggregated basis).
• The Vanguard Group, Inc. no longer has, or is deemed to have, beneficial ownership over securities beneficially owned by these subsidiaries and/or business divisions.
• These subsidiaries and business divisions continue to pursue the same investment strategies as previously pursued by The Vanguard Group, Inc. prior to the realignment.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this filing as neutral. It reflects a procedural change in how The Vanguard Group reports its beneficial ownership, not a change in its investment in Beam Therapeutics Inc. or the company's fundamentals.

Future Outlook

The filing does not contain any forward-looking statements or guidance regarding Beam Therapeutics Inc.'s operations or financial performance.

Management Comments

• The Vanguard Group, Inc. went through an internal realignment on January 12, 2026, leading to disaggregated reporting of beneficial ownership by its subsidiaries or business divisions.
• The Vanguard Group, Inc. no longer has, or is deemed to have, beneficial ownership over securities beneficially owned by such subsidiaries and/or business divisions.

Industry Context

StockSavvy.ai notes that internal realignments by large institutional investors like The Vanguard Group are typically procedural and reflect changes in reporting structure rather than a fundamental shift in investment strategy or a divestment from the underlying company. This type of filing is common for large asset managers managing numerous funds and accounts.

Stakeholder Impact

• Shareholders of Beam Therapeutics Inc. may initially perceive a large institutional investor reducing its stake, but the detailed explanation clarifies that this is a reporting change, not necessarily a full divestment by all Vanguard-managed funds. The actual impact on the shareholder base is likely minimal as the underlying investments may persist under different reporting entities.

Key Dates

Recommendation

The filing reflects a procedural change in how The Vanguard Group reports its beneficial ownership, not a fundamental change in its investment in Beam Therapeutics. The parent entity now reports 0% beneficial ownership, with subsidiaries reporting separately, which does not imply a divestment or a change in the investment thesis for Beam Therapeutics. Therefore, no new information warrants a change in investment recommendation.

Keywords

Beam Therapeutics, Vanguard Group, Schedule 13G, Beneficial Ownership, SEC Filing, Institutional Ownership, Corporate Realignment